VB6-845 is a humanized antibody fragment targeting EpCAM fused with the Company’s proprietary deimmunized form of the cytotoxin Bouganin and is designed for systemic use against metastatic cancer. VB6-845 has demonstrated effective cancer cell killing properties in pre-clinical tests. A full array of animal efficacy studies and safety studies of VB6-845 for the treatment of ovarian cancer and other solid tumors has been completed. In animal xenograft studies, VB6-845 elicited 100% complete cures of established ovarian tumors. VB6-845 has been shown to be safely tolerated in both primate and rodent animal safety studies